Patient P-01675
Therapy response
Unstable
Tolerance
Stable
GI state
Stable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −25% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 54 GI-04 recommended — GI Support Protocol GI-04
- Day 55 Patient accepted — Started GI-04 in the companion
- Day 63 No meaningful change — GI Support Protocol GI-04
- Day 63 ME-01 recommended — Monitoring Escalation ME-01
- Day 64 Patient accepted — Started ME-01 in the companion
- Day 67 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 52.
Primary contributors, last 14 days
- Treatment adherence-9
- Inflammatory activity+6
- GI instability+2
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −25%
- GI Support Protocol GI-04Day 54Result: no meaningful change
- Monitoring Escalation ME-01Day 63Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
67%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- Autonomic recovery ↑45
- WearableResting HR 81 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 58
- Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 46
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.8 · butyrate capacity 45/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 57 ms
- Sleep
- 6.2 h
- Steps
- 6,241
- Resting HR
- 80 bpm
Daily log: GI score 56, nutritional resilience 41, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01891 | 61% | S14 | SC-12 | improved | 41 |
| P-01494 | 60% | S14 | GI-04 | improved | 42 |
| P-01413 | 57% | S14 | GI-04 | improved | 44 |
| P-01598 | 57% | S14 | GI-04 | no change | 45 |
| P-01436 | 51% | S14 | GI-04 | improved | 38 |
| P-01834 | 51% | S14 | NP-02 | improved | 44 |
| P-01328 | 50% | S14 | SC-12 | no change | 49 |
| P-01539 | 50% | S14 | GI-04 | improved | 43 |
| P-01732 | 50% | S14 | ME-01 | improved | 45 |
| P-01782 | 50% | S14 | NP-02 | no change | 48 |
| P-01307 | 49% | S14 | GI-04 | improved | 43 |
| P-01389 | 49% | S14 | SC-12 | improved | 46 |